Q-omics provides the consensus-scored STX4 profile across patient tissues and cancer cell-line models. STX4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STX4 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, STX4 protein abundance shows 22,956 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRC, and UCEC as cancer lineages where STX4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STX4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STX4 survival associations across molecular data types. STX4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STX4 RNA expression–survival associations across cancer types. High STX4 expression shows unfavorable associations in KIRC, UVM, UCS and LIHC, but favorable associations in SKCM and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STX4 RNA expression.
This table summarizes STX4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for STX4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STX4 shows higher tumor expression in KIRC, HNSC, KIRP, LIHC, COAD and STAD. The KIRC box plot shows higher STX4 RNA expression in tumor versus normal tissue (log2 FC = +1.301, t-test p < 0.001).
This table shows molecular features associated with STX4 in patient tissues and cancer cell lines. In patient samples, STX4 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, STX4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
